Mesoblast Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mesoblast Ltd (MESO)
Mesoblast Ltd stock price live, this page displays NASDAQ MESO stock exchange data. View the MESO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mesoblast Ltd real time stock price chart below.
What Is the Mesoblast Ltd Stock Price Today?
The Mesoblast Ltd stock price today is 16.390.
What Is the Stock Symbol for Mesoblast Ltd?
The stock symbol for Mesoblast Ltd is "MESO."
What Stock Exchange Does Mesoblast Ltd Trade On?
Mesoblast Ltd is listed and trades on the NASDAQ stock exchange.
Is Mesoblast Ltd a Good Stock to Buy?
Determining whether Mesoblast Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MESO quote. (ISIN: US5907174016)
What Is the Mesoblast Ltd Stock Price Today?
The Mesoblast Ltd stock price today is 16.390.
What Is the Stock Symbol for Mesoblast Ltd?
The stock symbol for Mesoblast Ltd is "MESO."
What Stock Exchange Does Mesoblast Ltd Trade On?
Mesoblast Ltd is listed and trades on the NASDAQ stock exchange.
Is Mesoblast Ltd a Good Stock to Buy?
Determining whether Mesoblast Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MESO quote. (ISIN: US5907174016)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.390
16.720
52 wk Range
13.050
21.500
MESO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.39016.720
52 wk Range
13.05021.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MESO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
37.000
Upside
+125.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
- Mesoblast Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Why is Mesoblast stock surging today?- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 37.000
(+125.75% Upside)
Mesoblast Ltd Earnings Call Summary for H2/2026
- Mesoblast reported $115M revenue in FY2026, its first full commercial year, with Q4 at $36M; net loss narrowed 44% YoY to $57.5M.
- Stock fell 2.04% to $16.84 on slightly missed Q4 revenue forecast of $36.91M; recovered 0.95% after-hours to $17.00.
- Management guides double-digit RYONCIL revenue growth next 12 months, targeting profitability in FY2027 with lower cash burn expected.
- Adult GVHD trial enrolling across 40+ sites with interim analysis planned Q4 2027; pivotal Duchenne trial expected within 12 months.
- Cash balance of $103M plus $125M credit line deemed sufficient; company maintains capital-raising optionality to support pipeline expansion.
Last Updated: 08/27/2026, 07:34 AM
Read Full TranscriptEarnings
Latest Release
Aug 26, 2026
EPS / Forecast
-0.13 / --
Revenue / Forecast
68.91M / 36.91M
Compare MESO to Peers and Sector
Metrics to compare | MESO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMESOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.2x | −0.5x | −0.4x | |
PEG Ratio | −0.75 | 0.02 | 0.00 | |
Price/Book | 3.7x | 2.4x | 2.6x | |
Price / LTM Sales | 17.3x | 3.6x | 3.0x | |
Upside (Analyst Target) | 124.6% | 42.6% | 49.7% | |
Fair Value Upside | Unlock | 0.7% | 6.8% | Unlock |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mesoblast (MESO) Stock Price Today?
The Mesoblast stock price today is 16.390 USD.
What Stock Exchange Does Mesoblast Trade On?
Mesoblast is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Mesoblast?
The stock symbol for Mesoblast is "MESO."
What Is the Mesoblast Market Cap?
As of today, Mesoblast market cap is 2.150B USD.
What Is Mesoblast's Earnings Per Share (TTM)?
The Mesoblast EPS (TTM) is -0.044.
When Is the Next Mesoblast Earnings Date?
Mesoblast will release its next earnings report on Nov 25, 2026.
From a Technical Analysis Perspective, Is MESO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Mesoblast Stock Split?
Mesoblast has split 1 times.
How Many Employees Does Mesoblast Have?
Mesoblast has 108 employees.
What is the current trading status of Mesoblast (MESO)?
As of Sep 09, 2026, Mesoblast (MESO) is trading at a price of 16.390 USD, with a previous close of 16.390 USD. The stock has fluctuated within a day range of 16.390 USD to 16.720 USD, while its 52-week range spans from 13.050 USD to 21.500 USD.
What Is Mesoblast (MESO) Price Target According to Analysts?
The average 12-month price target for Mesoblast is 37.000 USD, with a high estimate of 39 USD and a low estimate of 35 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +125.75% Upside potential.
What Is the MESO After Hours Price?
MESO's last after hours stock price is 16.490 USD, the stock has decreased by 0.100, or 0.610%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.